A biotechnology executive with over two decades of leadership experience, Mark W. Schwartz, PhD, has held management positions with several companies, including Bayhill Therapeutics, Apthera, and Galena Biopharma. He currently serves as the director of Targazyme, Inc., and Chairman of MWS Strategic Advisors, LLC. Alongside his day-to-day professional pursuits, Dr. Mark W. Schwartz maintains membership in the American Society of Clinical Oncology (ASCO).
Each year, ASCO holds a variety of conferences, workshops, and other education events as part of its efforts to improve cancer care worldwide. The organization's largest event is its Annual Meeting, a multi-day conference that attracts more than 30,000 attendees from around the globe.
ASCO recently wrapped up its 2017 Annual Meeting, which was held June 2-6, 2017, at McCormick Place in Chicago. The highlight of the five-day event was an education program featuring didactic and panel discussions, symposia, poster presentations, and other learning activities on the latest research and treatments in cancer care.
Additionally, the meeting included a range of sessions on care delivery and practice management. More than 500 exhibiting companies were also on hand, so attendees had the opportunity to see the latest products and services in oncology.
The next ASCO Annual Meeting will be held in Chicago on June 1-5, 2018. Information about other ASCO programs and events can be found at www.asco.org.